1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-158791
    Enpp-1-IN-21
    Inhibitor 99.07%
    Enpp-1-IN-21 (compound 4g) is an inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), with IC50 values for ENPP1 and ENPP3 at 0.45 and 0.19 μM, respectively.
    Enpp-1-IN-21
  • HY-I0635
    (Rac)-Apremilast
    Inhibitor 99.53%
    (Rac)-Apremilast ((Rac)-CC-10004) is the racemic mixture of Apremilast. (Rac)-Apremilast has anti-inflammatory properties and can be used for research on inflammatory diseases, such as psoriasis.
    (Rac)-Apremilast
  • HY-106230A
    Dasantafil
    Inhibitor 98.35%
    Dasantafil (SCH-446132) is a small molecule phosphodiesterase-5A (PDE5A) inhibitor used to in genitourinary disorders and study erectile dysfunction.
    Dasantafil
  • HY-19830
    AN3199
    Inhibitor 99.76%
    AN3199 is a PDE4 inhibitor with an IC50 of 94.5 nM. AN3199 can be used for the research of inflammation-associated diseases such as asthma and chronic obstructive pulmonary disease (COPD).
    AN3199
  • HY-B0523
    Anagrelide
    Inhibitor 99.87%
    Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action.
    Anagrelide
  • HY-100933
    MY-5445
    Inhibitor 99.86%
    MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, phosphodiesterase type 5 (PDE5), with a Ki of 1.3 μM. MY-5445 inhibits human platelet aggregation. MY-5445 is a selective modulator of ATP-binding cassette (ABC) transporter ABCG2, with anti-proliferative effect.
    MY-5445
  • HY-126137
    PDE9-IN-1
    Inhibitor 99.70%
    PDE9-IN-1 is a potent, selective, and orally bioavailable phosphodiesterase-9A (PDE9A) Inhibitor with an IC50 of 8.7 nM.
    PDE9-IN-1
  • HY-U00186
    K134
    Inhibitor 99.84%
    K134 is a phosphodiesterase 3 (PDE3) inhibitor. The IC50s of K134 toward PDE3A, PDE3B, PDE5, PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 µM, respectively.
    K134
  • HY-I0636
    (R)-Apremilast
    Control 99.99%
    (R)-Apremilast ((R)-CC-10004) is a enantiomer of Apremilast.
    (R)-Apremilast
  • HY-100246
    CI-1044
    Inhibitor 98.02%
    CI-1044 is an orally active PDE4 inhibitor with IC50s of 0.29, 0.08, 0.56, 0.09 μM for PDE4A5, PDE4B2, PDE4C2 and PDE4D3, respectively.
    CI-1044
  • HY-14464
    PF-00489791
    Inhibitor 99.70%
    PF-00489791 (PF-489791) is a potent inhibitor of phosphodiesterase 5A with IC50 of 1.5 nM. PF-00489791 can enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
    PF-00489791
  • HY-119611A
    Thioquinapiperifil dihydrochloride
    Inhibitor 99.22%
    Thioquinapiperifil dihydrochloride (KF31327), a potent, selective and non-competitive phosphodiesterase-5 (PDE-5, IC50 of 0.074 nM) inhibitor, is used for sexual enhancement study.
    Thioquinapiperifil dihydrochloride
  • HY-13344A
    PF-8380 hydrochloride
    Inhibitor 98.59%
    PF-8380 hydrochloride is a potent autotaxin inhibitor with an IC50 of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.
    PF-8380 hydrochloride
  • HY-70069
    GSK256066 Trifluoroacetate
    Inhibitor 99.83%
    GSK256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor, with an IC50 of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary disease.
    GSK256066 Trifluoroacetate
  • HY-W003486
    5,7-Dichloropyrazolo[1,5-a]pyrimidine
    Inhibitor 99.69%
    5,7-Dichloropyrazolo[1,5-a]pyrimidine (fragment 5) is a pyrazolopyrimidine phosphodiesterase 10A (PDE10A) inhibitor (Ki=24 μM). 5,7-Dichloropyrazolo[1,5-a]pyrimidine can be used in the study of schizophrenia.
    5,7-Dichloropyrazolo[1,5-a]pyrimidine
  • HY-B1209
    Etofylline
    Inhibitor 99.72%
    Etofylline (7-(β-Hydroxyethyl) theophylline) is an oral bronchodilator with anti-inflammatory effects. Etofylline inhibits phosphodiesterase and prevents the degradation of cAMP (cyclic adenosine monophosphate), leading to smooth muscle relaxation, reducing inflammatory responses and improving respiratory function. Etofylline affects the development of zebrafish embryos.
    Etofylline
  • HY-19393
    SCH 351591
    Inhibitor 98.0%
    SCH 351591 is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 of 58 nM. SCH 351591 can inhibit all 4 PDE4 subtypes (A, B, C, and D). SCH 351591 has the potential for the asthma and chronic obstructive pulmonary disease (COPD) research.
    SCH 351591
  • HY-111410
    ATX inhibitor 1
    Inhibitor 99.30%
    ATX inhibitor 1 is a potent ATX (IC50=1.23 nM, FS-3 and 2.18 nM, bis-pNPP) inhibitor.
    ATX inhibitor 1
  • HY-105092
    Tetomilast
    Inhibitor ≥98.0%
    Tetomilast (OPC-6535) is a PDE4 inhibitor with potential for the research of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD).
    Tetomilast
  • HY-124768
    PDE12-IN-3
    Inhibitor 98.02%
    PDE12-IN-3 is a phosphodiesterase 12 (PDE12) inhibitor with a pXC50 of 7.68. Antiviral activity.
    PDE12-IN-3
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.